{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T10:13:17Z","timestamp":1793527997727,"version":"4.5.0"},"reference-count":226,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872504"],"award-info":[{"award-number":["81872504"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["320.6799.15018"],"award-info":[{"award-number":["320.6799.15018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wu Jieping Medical Foundation for Clinical Research","award":["81872504"],"award-info":[{"award-number":["81872504"]}]},{"name":"Wu Jieping Medical Foundation for Clinical Research","award":["320.6799.15018"],"award-info":[{"award-number":["320.6799.15018"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Bone metastasis is a common complication of many types of advanced cancer, including breast cancer. Bone metastasis may cause severe pain, fractures, and hypercalcemia, rendering clinical management challenging and substantially reducing the quality of life and overall survival (OS) time of breast cancer patients. Studies have revealed that bone metastasis is related to interactions between tumor cells and the bone microenvironment, and involves complex molecular biological mechanisms, including colonization, osteolytic destruction, and an immunosuppressive bone microenvironment. Agents inhibiting bone metastasis (such as bisphosphate and denosumab) alleviate bone destruction and improve the quality of life of breast cancer patients with bone metastasis. However, the prognosis of these patients remains poor, and the specific biological mechanism of bone metastasis is incompletely understood. Additional basic and clinical studies are urgently needed, to further explore the mechanism of bone metastasis and develop new therapeutic drugs. This review presents a summary of the molecular mechanisms and therapeutic strategies of bone metastasis of breast cancer, aiming to improve the quality of life and prognosis of breast cancer patients and provide a reference for future research directions.<\/jats:p>","DOI":"10.3390\/cancers14235727","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T08:29:58Z","timestamp":1669105798000},"page":"5727","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies"],"prefix":"10.3390","volume":"14","author":[{"given":"Lulian","family":"Pang","sequence":"first","affiliation":[{"name":"Department of Oncology, Anhui Medical University, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Anhui Medical University, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Anhui Medical University, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxue","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Oncology, Anhui Medical University, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Anhui Medical University, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runze","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Anhui Medical University, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anlong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Anhui Medical University, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Oncology, Anhui Medical University, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9881-8625","authenticated-orcid":false,"given":"Sheng","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Anhui Medical University, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaidong","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Anhui Medical University, Hefei 230601, China"},{"name":"Center for Translational Medicine, Anhui Medical University, Hefei 230032, China"},{"name":"Department of Oncology, Shenzhen Hospital of Southern Medical University, Shenzhen 518000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2008.05.044","article-title":"Osteotropic cancers: From primary tumor to bone","volume":"273","author":"Buijs","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_3","first-page":"1318","article-title":"Bone secondaries in breast cancer: The solitary metastasis","volume":"30","author":"Boxer","year":"1989","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/jbmr.3618","article-title":"Understanding the Bone in Cancer Metastasis","volume":"33","author":"Fornetti","year":"2018","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"ref_5","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast.1889","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ceb.2005.08.001","article-title":"Molecular requirements for epithelial-mesenchymal transition during tumor progression","volume":"17","author":"Huber","year":"2005","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1182\/blood.V90.11.4522","article-title":"Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice","volume":"90","author":"Bugge","year":"1997","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clinbiochem.2021.03.003","article-title":"Roles of matrix metalloproteinase-7 (MMP-7) in cancer","volume":"92","author":"Liao","year":"2021","journal-title":"Clin. Biochem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4048\/jbc.2020.23.e17","article-title":"Matrix Metallopeptidase 3 Polymorphisms: Emerging genetic Markers in Human Breast Cancer Metastasis","volume":"23","author":"Suhaimi","year":"2020","journal-title":"J. Breast Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1172\/JCI200422123","article-title":"Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer","volume":"114","author":"Boucharaba","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_12","first-page":"4","article-title":"The function of the vertebral veins and their role in the spread of metastases. 1940","volume":"312","author":"Batson","year":"1995","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/1097-0142(195105)4:3<610::AID-CNCR2820040312>3.0.CO;2-Q","article-title":"The role of the vertebral venous system in the metastasis of cancer to the spinal column; experiments with tumor-cell suspensions in rats and rabbits","volume":"4","author":"Coman","year":"1951","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-007-9109-4","article-title":"The bone microenvironment in metastasis; what is special about bone?","volume":"27","author":"Bussard","year":"2008","journal-title":"Cancer Metastasis Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1158\/0008-5472.CAN-11-3061","article-title":"Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases","volume":"72","author":"Hiraga","year":"2012","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: A fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1159\/000489184","article-title":"Molecular Regulation of Bone Metastasis Pathogenesis","volume":"46","author":"Wu","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: Causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3748\/wjg.v9.i6.1144","article-title":"Mechanism and its regulation of tumor-induced angiogenesis","volume":"9","author":"Gupta","year":"2003","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.4161\/onci.21990","article-title":"Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction","volume":"1","author":"Danilin","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hernandez, R., Wade, S., Reich, A., Pirolli, M., Liede, A., and Lyman, G. (2018). Incidence of bone metastases in patients with solid tumors: Analysis of oncology electronic medical records in the United States. BMC Cancer, 18.","DOI":"10.1186\/s12885-017-3922-0"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/CMAR.S155524","article-title":"Bone metastasis pattern in initial metastatic breast cancer: A population-based study","volume":"10","author":"Xiong","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.critrevonc.2017.04.008","article-title":"Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases","volume":"115","author":"Body","year":"2017","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Jensen, A., Jacobsen, J., N\u00f8rgaard, M., Yong, M., Fryzek, J., and S\u00f8rensen, H. (2011). Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-29"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canep.2019.05.013","article-title":"Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: A 12-year longitudinal nationwide healthcare database study","volume":"61","author":"Baek","year":"2019","journal-title":"Cancer Epidemiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","article-title":"Differences in Breast Cancer Survival by Molecular Subtypes in the United States","volume":"27","author":"Howlader","year":"2018","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic Behavior of Breast Cancer Subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_31","first-page":"10248","article-title":"Incidence, prognosis and nomograms of breast cancer with bone metastases at initial diagnosis: A large population-based study","volume":"13","author":"Yao","year":"2021","journal-title":"Am. J. Transl. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/annonc\/mdi191","article-title":"Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group","volume":"16","author":"Cleeland","year":"2005","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1200\/JCO.2013.51.7219","article-title":"Pain and nociception: Mechanisms of cancer-induced bone pain","volume":"32","author":"Falk","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3959(96)03267-8","article-title":"Malignant bone pain: Pathophysiology and treatment","volume":"69","author":"Mercadante","year":"1997","journal-title":"Pain"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1590\/S0004-27302005000500024","article-title":"Hypercalcemia of malignancy: Clinical features, diagnosis and treatment","volume":"49","author":"Farias","year":"2005","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JOP.2016.011155","article-title":"Cancer-Related Hypercalcemia","volume":"12","author":"Goldner","year":"2016","journal-title":"J. Oncol. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1023\/A:1020326219576","article-title":"The status of breast cancer management: Challenges and opportunities","volume":"75","author":"Hortobagyi","year":"2002","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3111\/13696998.2012.737883","article-title":"Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases","volume":"16","author":"Walker","year":"2013","journal-title":"J. Med. Econ."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1002\/cam4.4027","article-title":"Cardiovascular events in cancer patients with bone metastases-A Danish population-based cohort study of 23,113 patients","volume":"10","author":"Asdahl","year":"2021","journal-title":"Cancer Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.21037\/atm-21-4052","article-title":"Clinicopathological characteristics and prognostic risk factors of breast cancer patients with bone metastasis","volume":"9","author":"Pan","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Huang, Z., Hu, C., Liu, K., Yuan, L., Li, Y., Zhao, C., and Hu, C. (2020). Risk factors, prognostic factors, and nomograms for bone metastasis in patients with newly diagnosed infiltrating duct carcinoma of the breast: A population-based study. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07635-1"},{"key":"ref_44","first-page":"338","article-title":"Bone metastasis: Evaluation of 1100 patients with breast cancer","volume":"14","author":"Basdelioglu","year":"2021","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.21037\/apm-21-438","article-title":"Factors associated with bone metastasis in breast cancer: A systematic review and meta-analysis","volume":"10","author":"Liu","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10549-015-3352-0","article-title":"Retrospective analysis of metastatic behaviour of breast cancer subtypes","volume":"150","author":"Halfwerk","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/nm.2830","article-title":"Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape","volume":"18","author":"Bidwell","year":"2012","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccr.2009.05.017","article-title":"Latent bone metastasis in breast cancer tied to Src-dependent survival signals","volume":"16","author":"Zhang","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"17302","DOI":"10.18632\/aging.203211","article-title":"Bioinformatics analysis for the identification of key genes and long non-coding RNAs related to bone metastasis in breast cancer","volume":"13","author":"Teng","year":"2021","journal-title":"Aging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1258\/acb.2011.011040","article-title":"Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases","volume":"48","author":"Marin","year":"2011","journal-title":"Ann. Clin. Biochem."},{"key":"ref_51","first-page":"4814","article-title":"The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and the extent of metastasic spread in osseous metastatic breast cancer","volume":"25","author":"Pollmann","year":"2005","journal-title":"Anticancer. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10549-012-2374-0","article-title":"Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer","volume":"137","author":"Hess","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_53","first-page":"1353","article-title":"Physiology and pathophysiology of bone remodeling","volume":"45","author":"Raisz","year":"1999","journal-title":"Clin. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1158\/1055-9965.EPI-05-0909","article-title":"Alpha CTX as a biomarker of skeletal invasion of breast cancer: Immunolocalization and the load dependency of urinary excretion","volume":"15","author":"Leeming","year":"2006","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Kundaktepe, B.P., Sozer, V., Kundaktepe, F.O., Durmus, S., Papila, C., Uzun, H., Simsek, G., and Gelisgen, R. (2021). Association between Bone Mineral Density and Bone Turnover Markers in Breast Cancer Patients and Bone-Only Metastasis. Medicina, 57.","DOI":"10.3390\/medicina57090880"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.critrevonc.2011.02.005","article-title":"Consensus on the utility of bone markers in the malignant bone disease setting","volume":"80","author":"Coleman","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/clinchem\/47.1.74","article-title":"Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity","volume":"47","author":"Janckila","year":"2001","journal-title":"Clin. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bone.2003.04.002","article-title":"Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption","volume":"34","author":"Hannon","year":"2004","journal-title":"Bone"},{"key":"ref_59","first-page":"688","article-title":"Postoperative expressions of TRACP5b and CA125 in patients with breast cancer and their values for monitoring bone metastasis","volume":"25","author":"Feng","year":"2020","journal-title":"J. Buon"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1178223419830978","DOI":"10.1177\/1178223419830978","article-title":"Bone Metastasis Prognostic Factors in Breast Cancer","volume":"13","author":"Yazdani","year":"2019","journal-title":"Breast Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2354.2007.00826.x","article-title":"Bone and total alkaline phosphatase for screening skeletal metastasis in patients with solid tumours","volume":"17","author":"Schindler","year":"2008","journal-title":"Eur. J. Cancer Care"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/annonc\/mdm453","article-title":"Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas","volume":"19","author":"Alarmo","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1007\/s00330-013-2792-3","article-title":"MRI for response assessment in metastatic bone disease","volume":"23","author":"Lecouvet","year":"2013","journal-title":"Eur. Radiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s003300050548","article-title":"Magnetic resonance imaging of the bone marrow in hematological malignancies","volume":"8","author":"Berg","year":"1998","journal-title":"Eur. Radiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4329\/wjr.v7.i8.202","article-title":"Imaging of bone metastasis: An update","volume":"7","author":"Carty","year":"2015","journal-title":"World J. Radiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12149-011-0538-3","article-title":"FDG-avid sclerotic bone metastases in breast cancer patients: A PET\/CT case series","volume":"26","author":"Koolen","year":"2012","journal-title":"Ann. Nucl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.biopha.2012.06.004","article-title":"Early bone marrow metastasis detection: The additional value of FDG-PET\/CT vs. CT imaging","volume":"66","author":"Evangelista","year":"2012","journal-title":"Biomed. Pharmacother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10555-016-9631-3","article-title":"Estrogen, progesterone, and HER2\/neu receptor discordance between primary and metastatic breast tumours-a review","volume":"35","author":"Yeung","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4143\/crt.2011.43.2.89","article-title":"Implications of bone-only metastases in breast cancer: Favorable preference with excellent outcomes of hormone receptor positive breast cancer","volume":"43","author":"Lee","year":"2011","journal-title":"Cancer Res. Treat."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clbc.2019.02.001","article-title":"ER\/HER2 Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER\/HER2 Breast Cancer","volume":"19","author":"Arciero","year":"2019","journal-title":"Clin. Breast Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrm3254","article-title":"Building strong bones: Molecular regulation of the osteoblast lineage","volume":"13","author":"Long","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1677\/joe.0.1710229","article-title":"Estrogen receptor specificity in the regulation of the skeleton in female mice","volume":"171","author":"Lindberg","year":"2001","journal-title":"J. Endocrinol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1359\/jbmr.2001.16.8.1388","article-title":"Female estrogen receptor beta-\/- mice are partially protected against age-related trabecular bone loss","volume":"16","author":"Windahl","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cell.2007.07.025","article-title":"Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts","volume":"130","author":"Nakamura","year":"2007","journal-title":"Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1038\/s41467-021-25473-y","article-title":"Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer","volume":"12","author":"Wu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_76","first-page":"17","article-title":"Osteolytic effects of tumoral estrogen signaling in an estrogen receptor-positive breast cancer bone metastasis model","volume":"7","author":"Cheng","year":"2021","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","article-title":"Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors","volume":"88","author":"Fisher","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2013.07.006","article-title":"Omic-profiling in breast cancer metastasis to bone: Implications for mechanisms, biomarkers and treatment","volume":"40","author":"Wood","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1535-6108(03)00132-6","article-title":"A multigenic program mediating breast cancer metastasis to bone","volume":"3","author":"Kang","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Lin, Q., Fang, X., Liang, G., Luo, Q., Cen, Y., Shi, Y., Jia, S., Li, J., Yang, W., and Sanders, A. (2021). Silencing CTNND1 Mediates Triple-Negative Breast Cancer Bone Metastasis via Upregulating CXCR4\/CXCL12 Axis and Neutrophils Infiltration in Bone. Cancers, 13.","DOI":"10.3390\/cancers13225703"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jcla.20314","article-title":"Simplified and versatile method for bisulfite-based DNA methylation analysis of small amounts of DNA","volume":"23","author":"Tiwari","year":"2009","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_84","first-page":"1731","article-title":"The Drg-1 gene suppresses tumor metastasis in prostate cancer","volume":"63","author":"Bandyopadhyay","year":"2003","journal-title":"Cancer Res."},{"key":"ref_85","first-page":"749","article-title":"Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer","volume":"60","author":"Guan","year":"2000","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1038\/sj.onc.1207734","article-title":"Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression","volume":"23","author":"Bandyopadhyay","year":"2004","journal-title":"Oncogene"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1158\/0008-5472.CAN-05-0749","article-title":"Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases","volume":"65","author":"Kelly","year":"2005","journal-title":"Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2001.19.15.3562","article-title":"Biology of osteoclast activation in cancer","volume":"19","author":"Roodman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"953283","DOI":"10.3389\/fonc.2022.953283","article-title":"The Role of Osteopontin in Tumor Progression Through Tumor-Associated Macrophages","volume":"12","author":"Tan","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/978-3-030-73119-9_20","article-title":"Osteopontin Signaling in Shaping Tumor Microenvironment Conducive to Malignant Progression","volume":"1329","author":"Butti","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-016-0551-1","article-title":"Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis","volume":"15","author":"Marshall","year":"2016","journal-title":"Mol. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-021-00305-w","article-title":"IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer","volume":"7","author":"Tulotta","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature14282","article-title":"IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"Coffelt","year":"2015","journal-title":"Nature"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"8446629","DOI":"10.1155\/2022\/8446629","article-title":"Cancer-Associated Exosomal CBFB Facilitates the Aggressive Phenotype, Evasion of Oxidative Stress, and Preferential Predisposition to Bone Prometastatic Factor of Breast Cancer Progression","volume":"2022","author":"Hsu","year":"2022","journal-title":"Dis. Markers"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/jbmr.3891","article-title":"Extracellular Vesicles From Osteotropic Breast Cancer Cells Affect Bone Resident Cells","volume":"35","author":"Loftus","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1038\/cddis.2011.49","article-title":"Differentiation of hematopoietic stem cell and myeloid populations by ATP is modulated by cytokines","volume":"2","author":"Barbosa","year":"2011","journal-title":"Cell Death Dis."},{"key":"ref_97","first-page":"55","article-title":"Signaling pathways involved in MDSC regulation","volume":"1846","author":"Trikha","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.20150950","article-title":"Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer","volume":"213","author":"Mahajan","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/sj.bjc.6604794","article-title":"Cross talk of signals between EGFR and IL-6R through JAK2\/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas","volume":"100","author":"Colomiere","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/jbmr.3133","article-title":"Skeletal Colonization by Breast Cancer Cells Is Stimulated by an Osteoblast and \u03b22AR-Dependent Neo-Angiogenic Switch","volume":"32","author":"Mulcrone","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41571-021-00499-9","article-title":"Novel approaches to target the microenvironment of bone metastasis","volume":"18","author":"Hofbauer","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1440-1827.2010.02548.x","article-title":"CXCR4 and cancer","volume":"60","author":"Furusato","year":"2010","journal-title":"Pathol. Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.immuni.2006.10.016","article-title":"Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches","volume":"25","author":"Sugiyama","year":"2006","journal-title":"Immunity"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1038\/s41467-019-12807-0","article-title":"Microenvironmental IL1\u03b2 promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling","volume":"10","author":"Eyre","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrendo.2010.227","article-title":"Bone metastasis: Mechanisms and therapeutic opportunities","volume":"7","author":"Suva","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_107","first-page":"3059","article-title":"Localization of parathyroid hormone-related protein in breast cancer metastases: Increased incidence in bone compared with other sites","volume":"51","author":"Powell","year":"1991","journal-title":"Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1158\/1078-0432.CCR-17-3280","article-title":"Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling","volume":"24","author":"Tran","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/jbmr.3142","article-title":"PTHrP(12-48) Modulates the Bone Marrow Microenvironment and Suppresses Human Osteoclast Differentiation and Lifespan","volume":"32","author":"Kamalakar","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/345442a0","article-title":"The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene","volume":"345","author":"Yoshida","year":"1990","journal-title":"Nature"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.0105-2896.2005.00331.x","article-title":"alphavbeta3 and macrophage colony-stimulating factor: Partners in osteoclast biology","volume":"208","author":"Ross","year":"2005","journal-title":"Immunol. Rev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1084\/jem.190.12.1741","article-title":"Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors","volume":"190","author":"Arai","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1196\/annals.1443.016","article-title":"RANK\/RANKL: Regulators of immune responses and bone physiology","volume":"1143","author":"Leibbrandt","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bone.2006.09.023","article-title":"The molecular understanding of osteoclast differentiation","volume":"40","author":"Asagiri","year":"2007","journal-title":"Bone"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1084\/jem.20051150","article-title":"Autoamplification of NFATc1 expression determines its essential role in bone homeostasis","volume":"202","author":"Asagiri","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature02444","article-title":"Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis","volume":"428","author":"Koga","year":"2004","journal-title":"Nature"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"6158","DOI":"10.1073\/pnas.0401602101","article-title":"The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase","volume":"101","author":"Humphrey","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cmet.2013.01.002","article-title":"Tmem64 modulates calcium signaling during RANKL-mediated osteoclast differentiation","volume":"17","author":"Kim","year":"2013","journal-title":"Cell Metab."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","article-title":"The anti-tumor effect of RANKL inhibition in malignant solid tumors\u2014A systematic review","volume":"62","author":"Kroep","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/cr.2016.79","article-title":"Prevention of breast cancer by RANKL\/RANK blockade","volume":"26","author":"Galluzzi","year":"2016","journal-title":"Cell Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","article-title":"Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody","volume":"76","author":"Costa","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"25190","DOI":"10.1074\/jbc.272.40.25190","article-title":"TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells","volume":"272","author":"Wong","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"824117","DOI":"10.3389\/fimmu.2022.824117","article-title":"Roles of the RANKL-RANK Axis in Immunity-Implications for Pathogenesis and Treatment of Bone Metastasis","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41571-018-0095-y","article-title":"Roles of the RANKL-RANK axis in antitumour immunity\u2014Implications for therapy","volume":"15","author":"Ahern","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/jbmr.2294","article-title":"Human osteoclasts are inducible immunosuppressive cells in response to T cell-derived IFN-\u03b3 and CD40 ligand in vitro","volume":"29","author":"Li","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e1431088","DOI":"10.1080\/2162402X.2018.1431088","article-title":"RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer","volume":"7","author":"Ahern","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1200\/JCO.2013.51.3572","article-title":"Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma","volume":"34","author":"Smyth","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1158\/1078-0432.CCR-17-0606","article-title":"Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice","volume":"23","author":"Ahern","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nm.4076","article-title":"LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption","volume":"22","author":"Luo","year":"2016","journal-title":"Nat. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nature11000","article-title":"Osteoprotection by semaphorin 3A","volume":"485","author":"Hayashi","year":"2012","journal-title":"Nature"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1677\/joe.0.1730387","article-title":"Bone marrow and bone: A functional unit","volume":"173","author":"Compston","year":"2002","journal-title":"J. Endocrinol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0009-8981(99)00230-2","article-title":"Proteinases in bone resorption: Obvious and less obvious roles","volume":"291","author":"Engsig","year":"2000","journal-title":"Clin. Chim. Acta"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1432-0436.2002.700909.x","article-title":"Matrix metalloproteinases in tumor-host cell communication","volume":"70","author":"Lynch","year":"2002","journal-title":"Differ. Rev."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1158\/0008-5472.CAN-08-3949","article-title":"Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis","volume":"69","author":"Thiolloy","year":"2009","journal-title":"Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrc.2016.44","article-title":"Bone metastasis: The importance of the neighbourhood","volume":"16","author":"Croucher","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/01.bor.0000231909.35043.da","article-title":"New insights into the role of T cells in the vicious cycle of bone metastases","volume":"18","author":"Fournier","year":"2006","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"116014","DOI":"10.1016\/j.bone.2021.116014","article-title":"CD8 T cells from experimental in situ breast carcinoma interfere with bone homeostasis","volume":"150","author":"Monteiro","year":"2021","journal-title":"Bone"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/jbmr.4615","article-title":"Bone Microenvironment-Suppressed T Cells Increase Osteoclast Formation and Osteolytic Bone Metastases in Mice","volume":"37","author":"Arellano","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-12-2202","article-title":"Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer","volume":"73","author":"Sawant","year":"2013","journal-title":"Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/nm.1943","article-title":"Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis","volume":"15","author":"Korpal","year":"2009","journal-title":"Nat. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","article-title":"Breast cancer cells interact with osteoblasts to support osteoclast formation","volume":"140","author":"Thomas","year":"1999","journal-title":"Endocrinology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1172\/JCI3523","article-title":"TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development","volume":"103","author":"Yin","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Trivedi, T., Pagnotti, G.M., Guise, T.A., and Mohammad, K.S. (2021). The Role of TGF-beta in Bone Metastases. Biomolecules, 11.","DOI":"10.3390\/biom11111643"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1038\/onc.2015.297","article-title":"Myeloid-specific TGF-\u03b2 signaling in bone promotes basic-FGF and breast cancer bone metastasis","volume":"35","author":"Meng","year":"2016","journal-title":"Oncogene"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.biomaterials.2015.06.026","article-title":"Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin \u03b23 and TGF-\u03b2 receptor type II","volume":"64","author":"Page","year":"2015","journal-title":"Biomaterials"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1038\/s41467-022-30105-0","article-title":"EZH2 engages TGF\u03b2 signaling to promote breast cancer bone metastasis via integrin \u03b21-FAK activation","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4236\/abb.2013.410A4003","article-title":"\u03b2Role of TGF- in breast cancer bone metastases","volume":"4","author":"Chiechi","year":"2013","journal-title":"Adv. Biosci. Biotechnol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1158\/1078-0432.CCR-18-2697","article-title":"Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis","volume":"25","author":"Rieunier","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1359\/jbmr.2001.16.8.1486","article-title":"A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro","volume":"16","author":"Yoneda","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"13491","DOI":"10.1074\/jbc.M708055200","article-title":"VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism","volume":"283","author":"Zhang","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1210\/endo.140.8.6887","article-title":"Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation","volume":"140","author":"Lee","year":"1999","journal-title":"Endocrinology"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.4049\/jimmunol.169.6.3353","article-title":"IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae","volume":"169","author":"Palmqvist","year":"2002","journal-title":"J. Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/1078-0432.CCR-10-2507","article-title":"Molecular pathways: Osteoclast-dependent and osteoclast-independent roles of the RANKL\/RANK\/OPG pathway in tumorigenesis and metastasis","volume":"18","author":"Dougall","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","article-title":"Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: A potential role in multiple myeloma bone disease","volume":"100","author":"Giuliani","year":"2002","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1111\/cas.14606","article-title":"Caprylic acid (C8:0) promotes bone metastasis of prostate cancer by dysregulated adipo-osteogenic balance in bone marrow","volume":"111","author":"Wang","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jcp.2005.030031","article-title":"Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables","volume":"59","author":"Cross","year":"2006","journal-title":"J. Clin. Pathol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jcp.2005.030031","article-title":"Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours","volume":"59","author":"Cross","year":"2006","journal-title":"J. Clin. Pathol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1158\/1078-0432.CCR-18-2482","article-title":"Prognostic Value of RANKL\/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer","volume":"25","author":"Rachner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/jbmr.244","article-title":"Anticancer efficacy of Apo2L\/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo","volume":"26","author":"Zinonos","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00223-019-00573-6","article-title":"The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics","volume":"105","author":"Rochette","year":"2019","journal-title":"Calcif. Tissue Int."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ctrv.2008.03.006","article-title":"Antitumor effects of bisphosphonates: Promising preclinical evidence","volume":"34","author":"Guise","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-021-06100-2","article-title":"Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer","volume":"187","author":"Jallouk","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"JC22","DOI":"10.7326\/ACPJ201908200-022","article-title":"Review: Long-term alendronate or zoledronic acid reduces fractures in postmenopausal women with osteoporosis","volume":"171","author":"Bauer","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bone.2018.06.007","article-title":"Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial","volume":"114","author":"Kyvernitakis","year":"2018","journal-title":"Bone"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10549-018-4811-1","article-title":"A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: The ZAP trial","volume":"171","author":"Bardia","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.21.02647","article-title":"Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update","volume":"40","author":"Eisen","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2018.02.004","article-title":"Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01\/04) study","volume":"94","author":"Wilson","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: An open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: Final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jbo.2018.09.008","article-title":"Benefits and risks of adjuvant treatment with zoledronic acid in stage II\/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01\/04)","volume":"13","author":"Coleman","year":"2018","journal-title":"J. Bone Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"e12638","DOI":"10.1111\/ecc.12638","article-title":"Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study","volume":"27","author":"Khalafallah","year":"2018","journal-title":"Eur. J. Cancer Care"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1200\/JCO.2006.05.9212","article-title":"Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy","volume":"24","author":"Clemons","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1200\/JCO.2010.33.9150","article-title":"Denosumab for bone metastases from breast cancer: A new therapy option?","volume":"29","author":"Aapro","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nrendo.2011.18","article-title":"Breast cancer bone metastases: Denosumab or zoledronic acid?","volume":"7","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1200\/JCO.2010.33.5596","article-title":"Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: Incremental benefit, debatable value","volume":"29","author":"West","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): An international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1667\/RR3108","article-title":"Radiation treatment decreases bone cancer pain, osteolysis and tumor size","volume":"161","author":"Goblirsch","year":"2004","journal-title":"Radiat. Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/jrr\/rraa020","article-title":"Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer","volume":"61","author":"Tanaka","year":"2020","journal-title":"J. Radiat. Res."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijrobp.2009.10.056","article-title":"Radiotherapy for patients with metastases to the spinal column: A review of 603 patients at Shizuoka Cancer Center Hospital","volume":"79","author":"Mizumoto","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13014-015-0458-9","article-title":"Prognostic factors for survival of women with unstable spinal bone metastases from breast cancer","volume":"10","author":"Foerster","year":"2015","journal-title":"Radiat. Oncol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.clon.2021.09.018","article-title":"The Effect of Breast Cancer Subtype on Symptom Improvement Following Palliative Radiotherapy for Bone Metastases","volume":"34","author":"Sit","year":"2022","journal-title":"Clin. Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.radonc.2018.01.003","article-title":"Update of the systematic review of palliative radiation therapy fractionation for bone metastases","volume":"126","author":"Rich","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"100395","DOI":"10.1016\/j.jbo.2021.100395","article-title":"Concurrent capecitabine with external beam radiotherapy versus radiotherapy alone in painful bone metastasis of breast cancer origin","volume":"31","author":"Ahmed","year":"2021","journal-title":"J. Bone Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.2307\/3580112","article-title":"Alpha-particle doses to cells of the bone remodeling cycle from alpha-particle-emitting bone-seekers: Indications of an antiresorptive effect of actinides","volume":"152","author":"Salmon","year":"1999","journal-title":"Radiat. Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1158\/1078-0432.CCR-16-2955","article-title":"Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models","volume":"23","author":"Suominen","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/annonc\/mdw065","article-title":"Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study","volume":"27","author":"Nilsson","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.eururo.2017.06.021","article-title":"Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial","volume":"73","author":"Parker","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-014-2939-1","article-title":"A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease","volume":"145","author":"Coleman","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1158\/1078-0432.CCR-17-3577","article-title":"Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases","volume":"24","author":"McKay","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/jnci\/djt116","article-title":"Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis","volume":"105","author":"Suominen","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2162-3619-3-23","article-title":"Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone","volume":"3","author":"Takalkar","year":"2014","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/cam4.2780","article-title":"Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer","volume":"9","author":"Ueno","year":"2020","journal-title":"Cancer Med."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00003086-200203000-00029","article-title":"Surgical treatment of bone metastases in patients with breast cancer","volume":"396","author":"Lenz","year":"2002","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s00132-008-1374-6","article-title":"Prognosis-adapted surgical management of bone metastases","volume":"38","author":"Utzschneider","year":"2009","journal-title":"Der Orthop."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2106\/JBJS.H.00175","article-title":"Surgical management of metastatic bone disease","volume":"91","author":"Bickels","year":"2009","journal-title":"JBJS"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.acuro.2016.09.004","article-title":"Influence of the location and number of metastases in the survival of metastatic prostatic cancer patients","volume":"41","author":"Guijarro","year":"2017","journal-title":"Actas Urol. Esp."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/a-0762-1071","article-title":"Bone Metastases\u2014Pathophysiology, Diagnostic Testing and Therapy (Part 2)","volume":"157","author":"Koob","year":"2019","journal-title":"Z. Orthop. Unf."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study","volume":"34","author":"Nanda","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13058-018-1037-4","article-title":"Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models","volume":"20","author":"Rosato","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1172\/JCI133334","article-title":"PD-1 blockade inhibits osteoclast formation and murine bone cancer pain","volume":"130","author":"Wang","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"S1289","DOI":"10.1016\/j.annonc.2021.08.2089","article-title":"KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC","volume":"32","author":"Cortes","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/PPO.0000000000000497","article-title":"Immunotherapy in Triple-Negative Breast Cancer","volume":"27","author":"Emens","year":"2021","journal-title":"Cancer J."},{"key":"ref_220","first-page":"3817","article-title":"Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231","volume":"25","author":"Saito","year":"2005","journal-title":"Anticancer. Res."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.seminoncol.2003.08.019","article-title":"Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody","volume":"30","author":"Sato","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00280-015-2895-4","article-title":"Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors","volume":"76","author":"Fujiwara","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-16-1743","article-title":"TGF\u03b2R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells","volume":"23","author":"Tran","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1470-2045(22)00446-6","article-title":"Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: A single-arm, phase 2 trial","volume":"23","author":"Yamazaki","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41419-022-05086-z","article-title":"Targeting HIC1\/TGF-\u03b2 axis-shaped prostate cancer microenvironment restrains its progression","volume":"13","author":"Wu","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_226","unstructured":"Ghanaatgar-Kasbi, S., Pouya, F., Khoshghamat, N., Ghorbannezhad, G., Khazaei, M., Hasanzadeh, M.A., Ferns, G., and Avan, A. (Curr. Cancer Drug Targets, 2022). Targeting the transforming growth factor-beta signaling pathway in the treatment of gynecologic cancer, Curr. Cancer Drug Targets, ahead of print."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/5727\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:24:06Z","timestamp":1760145846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/5727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":226,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["cancers14235727"],"URL":"https:\/\/doi.org\/10.3390\/cancers14235727","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]}}}